POSB19 Matching-Adjusted Indirect Comparison of Trastuzumab Deruxtecan vs. Eribulin, Capecitabine, and Vinorelbine for Treating Human Epidermal Growth Factor Receptor 2-Positive Unresectable or Metastatic Breast Cancer after Two or More Ant ...
Jan 1, 2022, 00:00
10.1016/j.jval.2021.11.129
https://www.valueinhealthjournal.com/article/S1098-3015(21)01924-0/fulltext
Title :
POSB19 Matching-Adjusted Indirect Comparison of Trastuzumab Deruxtecan vs. Eribulin, Capecitabine, and Vinorelbine for Treating Human Epidermal Growth Factor Receptor 2-Positive Unresectable or Metastatic Breast Cancer after Two or More Ant ...
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)01924-0&doi=10.1016/j.jval.2021.11.129
First page :
Section Title :
Open access? :
No
Section Order :
10894